Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.

Our primary focus is to create quality outcomes for our:

  • Customers
  • Patients
  • Shareholders

Financial Calendar

Full Year End

31 December 2018

Half Year End

30 June 2018

Final Dividend Payment

15 June 2018

Annual General Meeting

6 June 2018

Preliminary Results Announcement

14 March 2018
View Full Calendar

Financial Reports

2017 Interim Report

September 2017

2016 Interim Report

September 2016

2015 Interim Report

October 2015

2014 Interim Report

September 2014
View All Reports

News

Authorised Economic Operator (AEO)

Our Winsford site (Advanced Medical Solutions Limited) has been approved for Authorised Economic Operator (AEO) status with effect from 1st April... Read More

View More News

Latest Financial Highlights

Summary

AMS continues to progress as a leading international provider of high quality, high value, innovative and technologically advanced products for the surgical and advanced wound care markets. We are pleased to report another year of strong revenue growth, profit performance and cash generation.

Our revenues increased 16% to £96.9 million (2016: £83.2 million), representing growth of 12% on a constant currency basis and our adjusted profit before tax increased by 29% to £25.4 million (2016: £19.7 million) and our profit before tax increased by 32% to £25.3 million (2016: £19.1 million). The continued strong cash generation of the business has resulted in the Group ending the year with net cash of £62.5 million (2016: £51.1 million).

Good progress has been made with all of our brands. LiquiBand® continues to do well in the US and we have gained a further 2% market share since we last reported to make our market share by volume to 26%. Revenue from our RESORBA® brands grew steadily across all territories and has grown by 15% and by 6% at constant currency to £20.8 million (2016: £18.1 million), while ActivHeal® grew by 4% to £6.3 million (2016: £6.0 million).

We were pleased to announce in October 2017 that we had agreed a patent out-licensing agreement with Organogenisis for a collagen based wound dressing containing Polyhexamethylene Biguanide (“PHMB”). Under this agreement, we receive royalties from Organogenesis’ net sales in the US on the product. The agreement is in place for the life of the patent which expires in October 2026.

AMS continues to be in robust financial health and we are continuing to grow our international footprint and scale. The Group is well positioned to increase investment in internal innovation and to actively pursue external opportunities in line with our long-term strategy and growth objectives.